Literature DB >> 18266322

Elucidation of the antimicrobial mechanism of mutacin 1140.

Leif Smith1, Hester Hasper, Eefjan Breukink, Jan Novak, Jirí Cerkasov, J D Hillman, Shawanda Wilson-Stanford, Ravi S Orugunty.   

Abstract

Mutacin 1140 and nisin A are peptide antibiotics that belong to the lantibiotic family. N-Terminal rings A and B of nisin A and mutacin 1140 (lipid II-binding domain) share many structural and sequence similarities. Nisin A binds lipid II and thus disrupts cell wall synthesis and also forms transmembrane pores. Very little is known about mutacin 1140 in this regard. We performed fluorescence-based studies using a bacteria-mimetic membrane system. The results indicated that lipid II monomers are arranged differently in the mutacin 1140 complex than in the nisin A complex. These differences in complex formation may be attributed to the fact that nisin A uses lipid II to form a distinct pore complex, while mutacin 1140 does not form pores in this membrane system. Further experiments demonstrated that the mutacin 1140-lipid II and nisin A-lipid II complexes are very stable and capable of withstanding competition from each other. Transmembrane electrical potential experiments using a Streptococcus rattus strain, which is sensitive to mutacin 1140, demonstrated that mutacin 1140 does not form pores in this strain even at a concentration 8 times higher than the minimum inhibitory concentration (MIC). Circular complexes of mutacin 1140 and nisin A were observed by electron microscopy, providing direct evidence for a lateral assembly mechanism for these antibiotics. Mutacin 1140 did exhibit a membrane disruptive function in another commonly used artificial bacterial membrane system, and its disruptive activity was enhanced by increasing amounts of anionic phospholipids.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18266322     DOI: 10.1021/bi701262z

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  25 in total

1.  Cell Wall-active Bacteriocins and Their Applications Beyond Antibiotic Activity.

Authors:  Clara Roces; Ana Rodríguez; Beatriz Martínez
Journal:  Probiotics Antimicrob Proteins       Date:  2012-12       Impact factor: 4.609

2.  Influence of Ca(2+) ions on the activity of lantibiotics containing a mersacidin-like lipid II binding motif.

Authors:  T Böttiger; T Schneider; B Martínez; H-G Sahl; I Wiedemann
Journal:  Appl Environ Microbiol       Date:  2009-05-08       Impact factor: 4.792

3.  In vivo cluster formation of nisin and lipid II is correlated with membrane depolarization.

Authors:  Menno B Tol; Danae Morales Angeles; Dirk-Jan Scheffers
Journal:  Antimicrob Agents Chemother       Date:  2015-04-13       Impact factor: 5.191

4.  Carboxyl Analogue of Mutacin 1140, a Scaffold for Lead Antibacterial Discovery.

Authors:  Jerome Escano; Akshaya Ravichandran; Bita Salamat; Leif Smith
Journal:  Appl Environ Microbiol       Date:  2017-06-30       Impact factor: 4.792

5.  Role of Streptococcus mutans eukaryotic-type serine/threonine protein kinase in interspecies interactions with Streptococcus sanguinis.

Authors:  Lin Zhu; Jens Kreth
Journal:  Arch Oral Biol       Date:  2010-04-08       Impact factor: 2.633

6.  Antibacterial Peptides: Opportunities for the Prevention and Treatment of Dental Caries.

Authors:  Adam Pepperney; Michael L Chikindas
Journal:  Probiotics Antimicrob Proteins       Date:  2011-06       Impact factor: 4.609

7.  Role of lipid II and membrane thickness in the mechanism of action of the lantibiotic bovicin HC5.

Authors:  Aline Dias Paiva; Eefjan Breukink; Hilário Cuquetto Mantovani
Journal:  Antimicrob Agents Chemother       Date:  2011-08-29       Impact factor: 5.191

8.  Site-directed mutations in the lanthipeptide mutacin 1140.

Authors:  Shaorong Chen; Shawanda Wilson-Stanford; William Cromwell; Jeffrey D Hillman; Adam Guerrero; Charlotte A Allen; Joseph A Sorg; Leif Smith
Journal:  Appl Environ Microbiol       Date:  2013-04-19       Impact factor: 4.792

Review 9.  Therapeutic potential of type A (I) lantibiotics, a group of cationic peptide antibiotics.

Authors:  Leif Smith; Jd Hillman
Journal:  Curr Opin Microbiol       Date:  2008-10-24       Impact factor: 7.934

10.  Pharmacodynamic activity of the lantibiotic MU1140.

Authors:  Oliver G Ghobrial; Hartmut Derendorf; Jeffery D Hillman
Journal:  Int J Antimicrob Agents       Date:  2008-10-02       Impact factor: 5.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.